Tikva Allocell Pte Ltd, a cell therapy company aiming to tackle difficult-to-treat cancers, has closed its Series A funding round with $8.0M. The company is developing "off-the-shelf" T cell therapies, utilizing its Second Generation Allogeneic EBV-Specific T cell (ALLO EBVST) platform.
Its mission is to create safe, effective, readily available, and affordable T cell therapies. This involves leveraging the excellent safety profile of ALLO EBVST and proprietary technologies designed to enhance the T cell's performance in treating various cancers.
